Geographic Variation in Rosiglitazone Use Surrounding FDA Warnings in the Department of Veterans Affairs

BACKGROUND: Geographic variation in the use of prescription drugs, particularly those deemed harmful by the FDA, may lead to variation in patient exposure to adverse drug events. One such drug is the glucose-lowering drug rosiglitazone, for which the FDA issued a safety alert on May 21, 2007, follow...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Manag Care Spec Pharm
Main Authors: Ahuja, Vishal, Sohn, Min-Woong, Birge, John R., Syverson, Chad, Budiman-Mak, Elly, Emanuele, Nicholas, Cooper, Jennifer M., Huang, Elbert S.
Formato: Artigo
Idioma:Inglês
Publicado em: Academy of Managed Care Pharmacy 2015
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4861222/
https://ncbi.nlm.nih.gov/pubmed/26679970
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18553/jmcp.2015.21.12.1214
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados